You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC ，EGFR(T790M)，alflutinib

Showing 1 - 25 of 4,595
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (Chemotherapy, Alflutinib plus chemo)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jan 25, 2022

Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Lung Cancer Stage IV
  • EGFR T790M
  • Seoul, MA, Korea, Republic of
    Samsung Medical Center
Jan 26, 2023

EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)

Recruiting
  • EGFR T790M
  • +3 more
  • Beijing, Beijing, China
    Junling Li
Jul 21, 2022

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    Lung Cancer Trial in Boston, Nashville

    Active, not recruiting
    • Lung Cancer
      • Boston, Massachusetts
      • +1 more
      Dec 28, 2022

      NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

      Terminated
      • Carcinoma, Non-Small-Cell Lung
      • Kashiwa, Chiba, Japan
      • +3 more
      Jan 31, 2023

      Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

      Not yet recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • EGFR T790M
      • Seoul, Korea, Republic of
        Samsung Medical Center
      May 18, 2022

      Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

      Active, not recruiting
      • Carcinoma, Non-Small-Cell Lung
        • Hollywood, Florida
        • +1 more
        Sep 29, 2021

        Lung Cancer Trial (Lazertinib 240 mg)

        Approved for marketing
        • Lung Cancer
        • Lazertinib 240 mg
        • (no location specified)
        Feb 15, 2022

        NSCLC With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors Trial in Seoul

        Active, not recruiting
        • Non-Small Cell Lung Cancer With EGFR T790M Mutation
        • +2 more
        • Seoul, Korea, Republic of
          Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
        Aug 8, 2021

        Non Small Cell Lung Cancer Trial in Worldwide (AZD9291)

        Active, not recruiting
        Has Results
        • Non Small Cell Lung Cancer
        • La Jolla, California
        • +43 more
        Nov 25, 2022

        Osimertinib for HK Chinese With Metastatic T790M Mutated

        Completed
        • Non-small Cell Lung Cancer
        • Hong Kong, China
        • +3 more
        Sep 7, 2021

        Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

        Recruiting
        • Bronchial Neoplasms
        • Cologne, Germany
        • +6 more
        Nov 2, 2022

        Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

        Active, not recruiting
        • Non Small Cell Lung Cancer Metastatic
        • Dublin, Ireland
        • +24 more
        Aug 23, 2022

        NSCLC Trial in Beijing, Nanjing, Suzhou (BPI-7711 Capsule)

        Completed
        • Non-small Cell Lung Cancer
        • BPI-7711 Capsule
        • Beijing, Beijing, China
        • +3 more
        May 13, 2022

        Lung Tumors, EGFR Gene Mutations Trial in Hwasun (Osimertinib)

        Completed
        • Lung Neoplasms
        • EGFR Gene Mutations
        • Hwasun, Jeonnam, Korea, Republic of
          Chonnam National University Hwasun Hospital
        Aug 1, 2021

        Metastatic NSCLC Trial in China (AC0010)

        Active, not recruiting
        • Metastatic Non-small Cell Lung Cancer
        • Beijing, Beijing, China
        • +16 more
        Sep 2, 2021

        Osimertinib in Advanced Non-Small Cell Lung Cancer EGFR-T790M

        Completed
        • Non Small Cell Lung Cancer
        • Oviedo, Asturias, Spain
        • +30 more
        Jun 1, 2022

        Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation Trial in Shanghai (Almonertinib, Pemetrexed, Carboplatin)

        Unknown status
        • Lung Cancer, Non-small Cell
        • +2 more
        • Shanghai, Shanghai, China
          Cancer hospital Fudan University
        Oct 15, 2020

        NSCLC Stage IV, EGFR T790M Trial in Shanghai (3rd generation EGFR-TKI, Consolidative SBRT)

        Recruiting
        • NSCLC Stage IV
        • EGFR T790M
        • 3rd generation EGFR-TKI
        • Consolidative SBRT
        • Shanghai, China
          Fudan University Shanghai Cancer Center
        Feb 19, 2021

        Testing in EGFRm NSCLC EGFR TKI 1L Across Europe (REFLECT)

        Completed
        • Lung Cancer
        • Non Interventional
        • Wien, Bulgaria
          Research Site
        Dec 22, 2020

        NSCLC Trial in Worldwide (PF-06747775, Palbociclib, Avelumab)

        Terminated
        Has Results
        • Non-Small Cell Lung Cancer
        • La Jolla, California
        • +14 more
        May 13, 2021

        NSCLC Trial in Worldwide (Osimertinib, Gefitinib)

        Active, not recruiting
        • NSCLC
        • Bordeaux, France
        • +21 more
        Mar 5, 2021

        Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

        Recruiting
        • Lung Neoplasms
        • +23 more
        • La Jolla, California
        • +35 more
        Oct 6, 2022

        Treatment, Treatment Side Effects Trial in China (YK-029A)

        Recruiting
        • Treatment
        • Treatment Side Effects
        • Hefei, Anhui, China
        • +34 more
        Mar 15, 2023